BREAKING NEWS: Pfizer CEO says a THIRD dose of Covid vaccine is needed as early as six months after two shots – and then vaccinated annually
- Albert Bourla, CEO of Pfizer, said it was “likely” that people will need a booster dose of the COVID-19 vaccine
- The potential booster shot is fired within 12 months of full vaccination
- Bourla said it is possible that people will need to be immunized against the novel coronavirus annually
Pfizer Inc’s CEO believes people will “likely” need a third dose of the COVID-19 vaccine.
During a panel discussion hosted by CNBC in partnership with CVS Health on April 1, Albert Bourla said a potential booster shot would be given six to 12 months after a full vaccination.
Bourla added that he believes it is possible that people will need to be immunized against coronavirus annually.
“There are vaccines like polio that do one dose … and there are vaccines like flu that you need every year,” he said on the segment that aired on Wednesday.
“The Covid virus is more like the influenza virus than the polio virus.”
Albert Bourla, CEO of Pfizer, said it was “likely” that people will need a booster dose of the COVID-19 vaccine
Pfizer and its German partner BioNTech began investigating a third dose of their vaccine in late February.
The booster shot aims to protect against future variants that may be better able to evade antibodies from the vaccine than previous strains of the virus.
Approximately 144 volunteers will be given the third dose, mostly those who participated in the U.S. early-stage vaccine testing last year.
The vaccine uses part of the pathogen’s genetic code called messenger RNA or mRNA to trick the body into recognizing the coronavirus and attacking it when a person becomes infected.
In the sting known as BNT162b2, the mRNA codes for all of the spike protein found on the outside of the virus that it uses to enter and infect cells.
It was approved for emergency use by the U.S. Food and Drug Administration (FDA) after a clinical study of 44,000 volunteers found the shot was 95 percent effective in preventing symptomatic COVID-19.
Six months later, real data showed that the vaccine offered 91 percent protection six months later.
However, the company’s current two-dose regimen resulted in a weaker immune response against the South African variant.
This is breaking news and will be updated.